Abstract: The present invention relates to methods of predicting the probability of an Oncotype DX® low risk recurrence score (RS) result (RS?25) for a breast cancer patient, to methods for selecting a breast cancer treatment, and to methods of treatment of breast cancer. It also relates to the use of a kit in these methods.

Abstract: The present invention relates to methods of predicting the probability of pathological complete response (pCR) of a breast cancer patient upon neo-adjuvant chemotherapy, to methods for selecting a breast cancer treatment, to methods of treatment of breast cancer, and to methods of prognosis of breast cancer upon breast cancer treatment.

Abstract: The present invention relates to an in vitro method of identifying a molecular subtype of a tumor in a cancer patient and to a method of stratifying a cancer patient for tumor treatment. The present invention further relates to kits that are useful for identifying a molecular subtype of a tumor in a cancer patient.

Abstract: The present invention relates to an in vitro method of identifying a molecular subtype of a tumor in a cancer patient and to a method of stratifying a cancer patient for tumor treatment. The present invention further relates to kits that are useful for identifying a molecular subtype of a tumor in a cancer patient.

Abstract: The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications.

Abstract: The present invention relates to an in vitro method of identifying a molecular subtype of a tumor in a cancer patient and to a method of stratifying a cancer patient for tumor treatment. The present invention further relates to kits that are useful for identifying a molecular subtype of a tumor in a cancer patient.

Abstract: The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications.

Abstract: The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications.

Abstract: The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene encoding for a ligand from the Vascular endothelial growth factor (VEGF) family and of and of at least one gene encoding for a receptor from the ErbB-family, or a gene co-expressed therewith, in said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern (s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen targeting the signalling pathway of said ligand and/or receptor is related to in said patient from the outcome of the comparison in step (c).

Abstract: A method for detecting or isolating disease-associated cells or pluripotent stem cells from body samples is provided where cells of a body sample are transfected with nucleic acid constructs that include the following components: (a) a promoter element containing at least one DNA site for binding one or more transcription factors; and (b) a reporter gene that enables the diseased or stem cells to be detected. When the method is used for detecting disease-associated cells, the transcription factor initiates at least one signalling activity in the disease-associated cells that is not present in healthy cells.

Abstract: In one embodiment, the invention provides methods for predicting a clinical outcome of a patient's neoplastic disease comprising: (a) determining a predictor value algorithmically using patient sample values for (1) at least one tumor marker or at least one immune marker, and (2) at least one marker that is (i) an extracellular matrix (ECM) marker (ii) a marker that is indicative of extracellular matrix synthesis (fibrogenesis), or (iii) a marker that is indicative of extracellular matrix degradation (fibrolysis); and (b) predicting the clinical outcome of the neoplastic disease by evaluating the predictor value.

Abstract: The present invention relates to an automatable method for the improved diagnosis of pathologically altered cells by simultaneously staining at least two different molecular markers, which exhibit a change in gene expression which is disease-associated, in a cell or constituent regions of a tissue sample by means of using combinations of antibodies and accrediting signal intensities.

Abstract: The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer in particular. Genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal people are disclosed.

Abstract: A method for detecting or isolating disease-associated cells or pluripotent stem cells from body samples is provided where cells of a body sample are transfected with nucleic acid constructs that include the following components: (a) a promoter element containing at least one DNA site for binding one or more transcription factors; and (b) a reporter gene that enables the diseased or stem cells to be detected. When the method is used for detecting disease-associated cells, the transcription factor initiates at least one signalling activity in the disease-associated cells that is not present in healthy cells.

Abstract: The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer in particular. Genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal people are disclosed.

Abstract: The present invention relates to an automatable method for the improved diagnosis of pathologically altered cells by simultaneously staining at least two different molecular markers, which exhibit a change in gene expression which is disease-associated, in a cell or constituent regions of a tissue sample by means of using combinations of antibodies and accrediting signal intensities.

Abstract: The present invention relates to an automatable method for obtaining an improved diagnosis of cancer, and its precancerous stages in uterine cervical smears by simultaneously staining and detecting at least two different molecular markers, which exhibit a disease-associated change in gene expression, in a cell by means of using antibodies or nucleic acid probes.